Pharma Globenewswire

TGF Beta Inhibitors Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

5 February 2026

DelveInsight’s “TGF Beta Inhibitors Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the TGF Beta Inhibitors pipeline landscape. It covers the TGF Beta Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also

Uncategorised

Bipolar Disorder Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

5 February 2026

DelveInsight’s “Bipolar Disorder Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Bipolar Disorder pipeline landscape. It covers the Bipolar Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bipolar

Uncategorised

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

5 February 2026

DelveInsight’s, “Advanced Liver Cancer Pipeline Insight 2025” Report provides comprehensive insights about 50+ companies and 52+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by

Uncategorised

Peanut Allergy Clinical Trial Pipeline Accelerates as 12+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

5 February 2026

DelveInsight’s, “Peanut Allergy Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the Peanut Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy

Clinical Trials

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

5 February 2026

Shilpa Biologicals Private Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, in collaboration with Switzerland-based mAbTree Biologics AG, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to their investigational biologic product. The designation covers a

Clinical Trials

FDA Grants Breakthrough Therapy Designation to Bezuclastinib Plus Sutent for Advanced GIST After GLEEVEC Failure

5 February 2026

The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bezuclastinib in combination with Sutent (sunitinib) for adults with advanced gastrointestinal stromal tumors (GIST) whose disease has progressed on, or become resistant to, GLEEVEC (imatinib), according to a recent update

Market Insights

Bispecific Antibody Pipeline Drugs and Companies Insight Report, 2025: Clinical, Commercial, and Developmental Analysis

4 February 2026

(Las Vegas, Nevada, United States) According to DelveInsight’s latest evaluation, the global bispecific antibody pipeline includes more than 180 active companies collectively developing over 250 bispecific antibody–based therapeutic candidates. The pipeline analysis provides a detailed overview of clinical trials, therapeutic approaches, mechanisms

Market Insights

Complicated Urinary Tract Infection Market Forecast to 2034 Shows Strong Growth, Driven by Antibiotic Innovation and Rising Disease Burden

4 February 2026

The Complicated Urinary Tract Infection (cUTI) market is expected to witness substantial growth through 2034, supported by rising disease prevalence, increasing antimicrobial resistance (AMR), and a robust late-stage antibiotic pipeline, according to DelveInsight’s Complicated Urinary Tract Infection Market Insights, Epidemiology, and Forecast

Market Insights

Clinical Trial Support Services Market Set to Hit USD 43.16B by 2032

4 February 2026

The global clinical trial support services market is set to witness sustained growth, driven by the rising burden of chronic diseases, increasing clinical trial volumes, and expanding pharmaceutical and biotechnology R&D pipelines. According to DelveInsight, the market is projected to reach USD

Latest

TGF Beta Inhibitors Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

Bipolar Disorder Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

Peanut Allergy Clinical Trial Pipeline Accelerates as 12+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

FDA Grants Breakthrough Therapy Designation to Bezuclastinib Plus Sutent for Advanced GIST After GLEEVEC Failure

Bispecific Antibody Pipeline Drugs and Companies Insight Report, 2025: Clinical, Commercial, and Developmental Analysis

Complicated Urinary Tract Infection Market Forecast to 2034 Shows Strong Growth, Driven by Antibiotic Innovation and Rising Disease Burden

Clinical Trial Support Services Market Set to Hit USD 43.16B by 2032

Recent Posts

Banner

Newsletter

Authors